Marfella Raffaele, D' Amico Michele, Di Filippo Clara, Siniscalchi Mario, Sasso Ferdinando Carlo, Ferraraccio Franca, Rossi Francesco, Paolisso Giuseppe
Department of Geriatrics and Metabolic Diseases, Second University of Naples, Italy.
Cardiovasc Diabetol. 2007 Oct 30;6:35. doi: 10.1186/1475-2840-6-35.
We have reviewed the impact of the ubiquitin proteasome system (UPS) on atherosclerosis progression of diabetic patients. A puzzle of many pieces of evidence suggests that UPS, in addition to its role in the removal of damaged proteins, is involved in a number of biological processes including inflammation, proliferation and apoptosis, all of which constitute important characteristics of atherosclerosis. From what can be gathered from the very few studies on the UPS in diabetic cardiovascular diseases published so far, the system seems to be functionally active to a different extent in the initiation, progression, and complication stage of atherosclerosis in the diabetic people. Further evidence for this theory, however, has to be given, for instance by specifically targeted antagonism of the UPS. Nonetheless, this hypothesis may help us understand why diverse therapeutic interventions, which have in common the ability to reduce ubiquitin-proteasome activity, can impede or delay the onset of diabetes and cardiovascular diseases (CVD). People with type 2 diabetes are disproportionately affected by CVD, compared with those without diabetes 1. The prevalence, incidence, and mortality from all forms of CVD (myocardial infarction, cerebro-vascular disease and congestive heart failure) are strikingly increased in persons with diabetes compared with those withoutdiabetes 2. Furthermore, diabetic patients have not benefited by the advances in the management of obesity, dyslipidemia, and hypertension that have resulted in a decrease in mortality for coronary heart disease (CHD) patients without diabetes 3. Nevertheless, these risk factors do not fully explain the excess risk for CHD associated with diabetes 45. Thus, the determinants of progression of atherosclerosis in persons with diabetes must be elucidated. Beyond the major risk factors, several studies have demonstrated that such factors, strictly related to diabetes, as insulin-resistance, post-prandial hyperglycemia and chronic hyperglycemia play a role in the atherosclerotic process and may require intervention 67. Moreover, it is important to recognize that these risk factors frequently "cluster" inindividual patients and possibly interact with each other, favouring the atherosclerosis progression toward plaque instability. Thus, a fundamental question is, "which is the common soil hypothesis that may unifying the burden of all these factors on atherosclerosis of diabetic patients? Because evidences suggest that insulin-resistance, diabetes and CHD share in common a deregulation of ubiquitin-proteasome system (UPS), the major pathway for nonlysosomal intracellular protein degradation in eucaryotic cells 89, in this review ubiquitin-proteasome deregulation is proposed as the common persistent pathogenic factor mediating the initial stage of the atherosclerosis as well as the progression to complicated plaque in diabetic patients.
我们回顾了泛素蛋白酶体系统(UPS)对糖尿病患者动脉粥样硬化进展的影响。众多证据表明,UPS除了在清除受损蛋白质方面发挥作用外,还参与了包括炎症、增殖和凋亡在内的许多生物学过程,所有这些都是动脉粥样硬化的重要特征。从目前发表的关于UPS在糖尿病心血管疾病方面的极少研究中可以看出,该系统在糖尿病患者动脉粥样硬化的起始、进展和并发症阶段似乎在不同程度上具有功能活性。然而,还需要进一步的证据来支持这一理论,例如通过对UPS进行特异性靶向拮抗。尽管如此,这一假设可能有助于我们理解为什么各种具有降低泛素 - 蛋白酶体活性能力的治疗干预措施能够阻碍或延缓糖尿病和心血管疾病(CVD)的发生。与非糖尿病患者相比,2型糖尿病患者受CVD的影响更大。与非糖尿病患者相比,糖尿病患者中所有形式的CVD(心肌梗死、脑血管疾病和充血性心力衰竭)的患病率、发病率和死亡率显著增加。此外,肥胖、血脂异常和高血压管理方面的进展使非糖尿病冠心病(CHD)患者的死亡率降低,但糖尿病患者并未从中受益。然而,这些风险因素并不能完全解释与糖尿病相关的CHD额外风险。因此,必须阐明糖尿病患者动脉粥样硬化进展的决定因素。除了主要风险因素外,多项研究表明,与糖尿病密切相关的因素,如胰岛素抵抗、餐后高血糖和慢性高血糖,在动脉粥样硬化过程中起作用,可能需要进行干预。此外,重要的是要认识到这些风险因素在个体患者中经常“聚集”,并可能相互作用,促进动脉粥样硬化向斑块不稳定发展。因此,一个基本问题是,“哪种共同土壤假说可以统一所有这些因素对糖尿病患者动脉粥样硬化的影响?”因为有证据表明胰岛素抵抗、糖尿病和CHD共同存在泛素 - 蛋白酶体系统(UPS)失调,这是真核细胞中非溶酶体细胞内蛋白质降解的主要途径,在本综述中,泛素 - 蛋白酶体失调被认为是介导糖尿病患者动脉粥样硬化初始阶段以及向复杂斑块进展的共同持续致病因素。